Mersana Therapeutics (MRSN) Competitors $1.60 -0.14 (-8.05%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends MRSN vs. COLL, SEPN, BCAX, ZYME, GYRE, PSTX, COGT, PAHC, NUVB, and AVBPShould you be buying Mersana Therapeutics stock or one of its competitors? The main competitors of Mersana Therapeutics include Collegium Pharmaceutical (COLL), Septerna (SEPN), Bicara Therapeutics (BCAX), Zymeworks (ZYME), Gyre Therapeutics (GYRE), Poseida Therapeutics (PSTX), Cogent Biosciences (COGT), Phibro Animal Health (PAHC), Nuvation Bio (NUVB), and ArriVent BioPharma (AVBP). These companies are all part of the "pharmaceutical products" industry. Mersana Therapeutics vs. Collegium Pharmaceutical Septerna Bicara Therapeutics Zymeworks Gyre Therapeutics Poseida Therapeutics Cogent Biosciences Phibro Animal Health Nuvation Bio ArriVent BioPharma Collegium Pharmaceutical (NASDAQ:COLL) and Mersana Therapeutics (NASDAQ:MRSN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, community ranking, risk, institutional ownership, earnings and analyst recommendations. Which has more volatility and risk, COLL or MRSN? Collegium Pharmaceutical has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, Mersana Therapeutics has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500. Do institutionals & insiders believe in COLL or MRSN? 93.9% of Mersana Therapeutics shares are held by institutional investors. 4.0% of Collegium Pharmaceutical shares are held by insiders. Comparatively, 11.8% of Mersana Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media refer more to COLL or MRSN? In the previous week, Collegium Pharmaceutical had 2 more articles in the media than Mersana Therapeutics. MarketBeat recorded 4 mentions for Collegium Pharmaceutical and 2 mentions for Mersana Therapeutics. Collegium Pharmaceutical's average media sentiment score of 1.04 beat Mersana Therapeutics' score of 0.85 indicating that Collegium Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Collegium Pharmaceutical 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mersana Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer COLL or MRSN? Collegium Pharmaceutical received 136 more outperform votes than Mersana Therapeutics when rated by MarketBeat users. However, 65.87% of users gave Mersana Therapeutics an outperform vote while only 65.25% of users gave Collegium Pharmaceutical an outperform vote. CompanyUnderperformOutperformCollegium PharmaceuticalOutperform Votes38565.25% Underperform Votes20534.75% Mersana TherapeuticsOutperform Votes24965.87% Underperform Votes12934.13% Which has preferable valuation and earnings, COLL or MRSN? Collegium Pharmaceutical has higher revenue and earnings than Mersana Therapeutics. Mersana Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCollegium Pharmaceutical$599.25M1.60$48.15M$2.3212.80Mersana Therapeutics$36.85M5.36-$171.67M-$0.61-2.62 Do analysts recommend COLL or MRSN? Collegium Pharmaceutical presently has a consensus target price of $42.60, indicating a potential upside of 43.43%. Mersana Therapeutics has a consensus target price of $6.00, indicating a potential upside of 275.00%. Given Mersana Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Mersana Therapeutics is more favorable than Collegium Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Collegium Pharmaceutical 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60Mersana Therapeutics 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.88 Is COLL or MRSN more profitable? Collegium Pharmaceutical has a net margin of 14.78% compared to Mersana Therapeutics' net margin of -214.20%. Collegium Pharmaceutical's return on equity of 104.67% beat Mersana Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Collegium Pharmaceutical14.78% 104.67% 18.38% Mersana Therapeutics -214.20%-401.37%-38.61% SummaryCollegium Pharmaceutical beats Mersana Therapeutics on 10 of the 19 factors compared between the two stocks. Ad Behind the MarketsWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol Get Mersana Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MRSN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRSN vs. The Competition Export to ExcelMetricMersana TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$197.65M$6.57B$5.10B$9.07BDividend YieldN/A2.97%4.90%4.21%P/E Ratio-2.6210.5591.0817.15Price / Sales5.36195.381,113.51116.81Price / CashN/A57.1642.2637.86Price / Book5.165.104.784.78Net Income-$171.67M$151.51M$119.77M$225.60M7 Day Performance-25.58%-2.12%-1.87%-1.23%1 Month Performance-19.31%-3.11%11.46%3.07%1 Year Performance-17.53%11.52%30.53%16.48% Mersana Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRSNMersana Therapeutics4.4085 of 5 stars$1.60-8.0%$6.00+275.0%-16.2%$197.65M$36.85M-2.62150Gap DownCOLLCollegium Pharmaceutical3.8334 of 5 stars$30.57+1.6%$42.60+39.4%-0.4%$985.88M$599.25M12.97210News CoveragePositive NewsSEPNSepterna2.2145 of 5 stars$22.05-1.5%$43.67+98.0%N/A$979.02MN/A0.00N/ABCAXBicara TherapeuticsN/A$17.57+0.4%$43.00+144.7%N/A$956.09MN/A0.0032Gap DownZYMEZymeworks2.8309 of 5 stars$13.75+9.3%$18.83+37.0%+52.5%$947.10M$76.01M-9.25290Analyst ForecastNews CoverageGap DownGYREGyre Therapeutics0.6035 of 5 stars$10.12+5.0%N/A-61.2%$946.43M$105.03M0.0040News CoveragePositive NewsPSTXPoseida Therapeutics3.7439 of 5 stars$9.52+0.1%$9.50-0.2%+193.5%$930.77M$64.70M-15.10260Positive NewsCOGTCogent Biosciences1.95 of 5 stars$8.35+2.5%$14.83+77.6%+51.9%$922.34MN/A-3.2980PAHCPhibro Animal Health4.1258 of 5 stars$22.71+0.2%$19.00-16.3%+89.6%$919.82M$1.05B52.561,940Analyst ForecastNUVBNuvation Bio2.3915 of 5 stars$2.71+3.8%$6.60+143.5%+90.1%$912.11MN/A0.0060News CoverageAVBPArriVent BioPharma0.9763 of 5 stars$26.78+0.2%$36.80+37.4%N/A$902.41MN/A0.0040News CoveragePositive News Related Companies and Tools Related Companies COLL Competitors SEPN Competitors BCAX Competitors ZYME Competitors GYRE Competitors PSTX Competitors COGT Competitors PAHC Competitors NUVB Competitors AVBP Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MRSN) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mersana Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mersana Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MRSN Stock Alerts